APO-PRAMIPEXOLE 0.125 MG
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE : 0.125 MG · DIN 02347342 · APOTEX INC
Health Canada status: APPROVED
What is APO-PRAMIPEXOLE?
APO-PRAMIPEXOLE 0.125 MG contains PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE : 0.125 MG. It is listed in the Health Canada Drug Product Database under DIN 02347342, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as approved, status dated 30-Mar-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02347342 |
|---|---|
| Brand name | APO-PRAMIPEXOLE |
| Generic / active ingredient | PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE : 0.125 MG |
| Manufacturer | APOTEX INC |
| Strength | 0.125 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04BC05 PRAMIPEXOLE |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 30-Mar-2010 |
What can be used instead?
Other Canadian products sharing ATC code N04BC05 PRAMIPEXOLE. 29 of 65 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT PRAMIPEXOLE | 0.25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02297302 |
| ACT PRAMIPEXOLE | 0.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02297310 |
| ACT PRAMIPEXOLE | 1 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02297329 |
| ACT PRAMIPEXOLE | 1.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02297337 |
| APO-PRAMIPEXOLE | 0.25 MG | TABLET | APOTEX INC | MARKETED | DIN 02292378 |
| APO-PRAMIPEXOLE | 0.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02292386 |
| APO-PRAMIPEXOLE | 1.0 MG | TABLET | APOTEX INC | MARKETED | DIN 02292394 |
| APO-PRAMIPEXOLE | 1.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02292408 |
| AURO-PRAMIPEXOLE | 0.25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02424061 |
| AURO-PRAMIPEXOLE | 0.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02424088 |
Who else supplies PRAMIPEXOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PRAMIPEXOLE appears in 2459 registered pack listings across 11 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.